Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

This year, Summit Therapeutics Inc. (SMMT) leads the parade of winners among large stocks (those with a market value of $10 billion or more).

In terms of valuation, Summit Therapeutics Inc’s market capitalization stands at $14.71 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

On Thursday, Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $18.59 which represents a decrease of $-0.06 or -0.32% from the prior close of $18.65. The stock opened at $18.75 and ...

JMP Securities initiated coverage of Summit Therapeutics (SMMT) with an Outperform rating and $32 price target The firm acknowledges the risk associated with data obtained from Chinese patients only, ...

Summit Therapeutics PLC ( (SMMT) ) has realeased its Q3 earnings. Here is a breakdown of the information Summit Therapeutics PLC presented to ...

Summit Therapeutics Inc's innovative approach to combating serious infectious diseases positions it as a potential leader in ...

Still, shares of Summit Therapeutics (NASDAQ: SMMT) are up by more than 989% in the last 12 months as I write this, and that's reason enough for investors to wonder if it might be a stock that's ...

Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise notably Monday, on the happy news that an analyst has initiated coverage ...

Summit Therapeutics targets potential $17.9 billion in peak revenue in NSCLC market by 2034. JMP Securities initiated coverage on Summit Therapeutics Inc. SMMT, noting the company’s initial ...